Form 4: Cue Biopharma SVP, General Counsel Colin Sandercock Reports Stock Option Grant

Colin Sandercock, SVP and General Counsel of Cue Biopharma, Inc., reports the acquisition of stock options.

Summary

• On June 5, 2024, Colin Sandercock, the SVP and General Counsel of Cue Biopharma, Inc., reported the acquisition of 60,000 stock options.
• The options have an exercise price of $1.65.
• The options become exercisable in eight equal semi-annual installments beginning on December 5, 2024.
• The expiration date for the options is June 4, 2034.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment as it simply reports a stock option grant, a routine part of executive compensation. It doesn't inherently indicate positive or negative performance.

Positives

• The grant of stock options to a key executive aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock price.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their executives.
• The vesting schedule of eight equal semi-annual installments is fairly typical, providing a balance between short-term and long-term incentives.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates